NF-kappaB in pancreatic cancer
- PMID: 12909735
- DOI: 10.1385/IJGC:33:1:15
NF-kappaB in pancreatic cancer
Abstract
Although the genetic profile of pancreatic cancer is emerging as a result of much research, the role of specific genetic alterations that initiate tumorigenesis and produce its cardinal clinical features of locally aggressive growth, metastasis, and chemotherapy resistance remains unresolved. Recently, a number of studies have shown that the inhibition of constitutive NF-kappaB activation, one of the frequent molecular alterations in pancreatic cancer, inhibits tumorigenesis and metastasis. It also sensitizes pancreatic cancer cell lines to anticancer agent-induced apoptosis. Therefore because of the crucial role of NF-kappaB in pancreatic cancer, it is a potential target for developing novel therapeutic strategies for the disease. In vivo and in vitro models that mimic the tumorigenic phenotypes in the appropriate histological and molecular concert would be very useful for confirming the suspected role of the pancreatic cancer signature genetic lesions and better understanding the molecular basis of this disease.
Similar articles
-
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.Oncogene. 2003 Mar 6;22(9):1365-70. doi: 10.1038/sj.onc.1206323. Oncogene. 2003. PMID: 12618762
-
The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.Biochim Biophys Acta. 2015 Dec;1849(12):1375-84. doi: 10.1016/j.bbagrm.2015.10.014. Epub 2015 Oct 22. Biochim Biophys Acta. 2015. PMID: 26477488
-
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.Oncogene. 2002 Sep 19;21(42):6510-9. doi: 10.1038/sj.onc.1205848. Oncogene. 2002. PMID: 12226754
-
The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.Pancreas. 2008 Apr;36(3):225-35. doi: 10.1097/MPA.0b013e31815b3207. Pancreas. 2008. PMID: 18362834 Review.
-
[Molecular mechanism in pathogenesis in pancreatic neoplasms: NF-kappaB].Nihon Rinsho. 2006 Jan;64 Suppl 1:44-7. Nihon Rinsho. 2006. PMID: 16457219 Review. Japanese. No abstract available.
Cited by
-
Genetically engineered mouse models of pancreatic adenocarcinoma.Mol Oncol. 2013 Apr;7(2):232-47. doi: 10.1016/j.molonc.2013.02.002. Epub 2013 Feb 11. Mol Oncol. 2013. PMID: 23506980 Free PMC article. Review.
-
Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.Theranostics. 2018 May 11;8(12):3224-3236. doi: 10.7150/thno.23259. eCollection 2018. Theranostics. 2018. PMID: 29930725 Free PMC article.
-
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.Int J Cancer. 2008 Aug 15;123(4):958-66. doi: 10.1002/ijc.23610. Int J Cancer. 2008. Retraction in: Int J Cancer. 2016 Nov 1;139(9):2146. doi: 10.1002/ijc.30270. PMID: 18528859 Free PMC article. Retracted.
-
DEPTOR has growth suppression activity against pancreatic cancer cells.Oncotarget. 2014 Dec 30;5(24):12811-9. doi: 10.18632/oncotarget.2659. Oncotarget. 2014. PMID: 25544749 Free PMC article.
-
Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae.PLoS One. 2013 Apr 16;8(4):e61977. doi: 10.1371/journal.pone.0061977. Print 2013. PLoS One. 2013. PMID: 23613993 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical